Previous 10 | Next 10 |
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
2024-04-24 18:28:32 ET Summary The Inflation Reduction Act has reduced the exclusivity period for small-molecule drugs, potentially leading to earlier market entry for generic drugs. The shortened exclusivity period may create a bullish catalyst for certain stocks in the generic p...
2024-04-24 14:06:00 ET Gilead Sciences ( NASDAQ: GILD ) is scheduled to announce Q1 earnings results on Thursday, April 25th, after market close.... Read the full article on Seeking Alpha For further details see: Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidanc...
2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...
2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...
2024-04-23 09:00:03 ET Summary GILD stock has given up most of its late-2022 gains due to sector-wide underperformance and disappointing data from the EVOKE-01 Phase 3 trial. Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Hence, and considering my last art...
2024-04-22 15:04:08 ET Summary The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. ...
2024-04-22 14:20:23 ET Summary Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design. A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation of approximately $72.53. Positive data ...
2024-04-22 13:04:43 ET Summary Heightened geopolitical risk has caught investors flat-footed over the past week. A historical analogy is presented of the Cuban Missile Crisis, a time of even greater geopolitical risk. In the short term, selling pressure in the market is likely...
2024-04-22 12:03:00 ET Summary The stock of Gilead Sciences, Inc. has underperformed the market substantially over the past decade, but there are some signs developing of a potential bottom. The stock offers a high dividend yield of 4.61% and is trading at a low valuation compared...
News, Short Squeeze, Breakout and More Instantly...
– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Im...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor, Dr. Parsey will continue as Chief Medical Officer until the first quarter of 2025 and support this trans...